RecruitingNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Studying Sarcoma of cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Adela, Inc
Principal Investigator
Brian Rini, MD
Vanderbilt-Ingram Cancer Center
Enrollment
7000 enrolled
Eligibility
40 years · All sexes
Timeline
20222027

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05366881 on ClinicalTrials.gov

Other trials for Sarcoma of cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Sarcoma of cervix uteri

← Back to all trials